Global expression of noncoding RNome reveals dysregulation of small RNAs in patients with HTLV-1-associated adult T-cell leukemia: a pilot study

Imagem de Miniatura
Arquivos
art_NASCIMENTO_Global_expression_of_noncoding_RNome_reveals_dysregulation_of_2021.PDF (2.6 MB)
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMC
Autores
NASCIMENTO, Andrezza
SOUZA, Daniela Raguer Valadao de
OLIVEIRA, Augusto Cesar Penalva de
LOUREIRO, Paula
Citação
INFECTIOUS AGENTS AND CANCER, v.16, n.1, article ID 4, 13p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Adult T cell lymphoma/leukemia (ATLL) is a peripheral T-cell neoplasm caused by human T-cell lymphotropic virus-1 (HTLV-1). Small RNAs (sRNAs), including microRNAs (miRNAs), play a pivotal role in the initiation and development of hematological malignancies and may represent potential therapeutic target molecules. However, little is known about how these molecules impact the pathogenesis of ATLL. In this study, we aimed to identify sRNA expression signatures associated with ATLL and to investigate their potential implication in the pathophysiology of the disease. Methods Small-RNAseq analysis was performed in peripheral blood mononuclear cells from HTLV-1- associated ATLL (n = 10) in comparison to asymptomatic carriers (n = 8) and healthy controls (n = 5). Sequencing was carried out using the Illumina MiSeq platform, and the deregulation of selected miRNAs was validated by real-time PCR. Pathway analyses of most deregulated miRNA were performed and their global profiling was combined with transcriptome data in ATLL. Results The sequencing identified specific sRNAs signatures associated with ATLL patients that target pathways relevant in ATLL, such as the transforming growth factor-(beta TGF-beta), Wnt, p53, apoptosis, and mitogen-activated protein kinase (MAPK) signaling cascades. Network analysis revealed several miRNAs regulating highly connected genes within the ATLL transcriptome. miR-451-3p was the most downregulated miRNA in active patients. Conclusions Our findings shed light on the expression of specific sRNAs in HTLV-1 associated ATLL, which may represent promising candidates as biomarkers that help monitor the disease activity.
Palavras-chave
Small RNA, HTLV-1, T cell antigen receptor, Asymptomatic carriers, Massively parallel sequencing
URI
https://observatorio.fm.usp.br/handle/OPI/39018
Referências
  1. Ansari KI, 2015, CELL REP, V11, P902, DOI 10.1016/j.celrep.2015.04.016
  2. Baltimore D, 2008, NAT IMMUNOL, V9, P839, DOI 10.1038/ni.f.209
  3. Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
  4. Bellon M, 2009, BLOOD, V113, P4914, DOI 10.1182/blood-2008-11-189845
  5. Cameron JE, 2008, VIROLOGY, V382, P257, DOI 10.1016/j.virol.2008.09.018
  6. Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903
  7. Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200
  8. Cheng WZ, 2019, BIOCHEM BIOPH RES CO, V512, P598, DOI 10.1016/j.bbrc.2019.03.094
  9. Clissa PB, 2016, DATA BRIEF, V9, P685, DOI 10.1016/j.dib.2016.09.052
  10. Dashwood Michael R, 2012, Methods Mol Biol, V878, P137, DOI 10.1007/978-1-61779-854-2_9
  11. Dong HF, 2013, CHEM REV, V113, P6207, DOI 10.1021/cr300362f
  12. Dong H, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-S3-S16
  13. Fochi S, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040290
  14. Fochi S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00285
  15. Franchini Genoveffa, 2000, Hematology Am Soc Hematol Educ Program, P409
  16. Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
  17. Gal H, 2008, BIOCHEM BIOPH RES CO, V376, P86, DOI 10.1016/j.bbrc.2008.08.107
  18. Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179
  19. Gazon H, 2016, ONCOTARGET, V7, P30258, DOI 10.18632/oncotarget.7162
  20. Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
  21. Giam CZ, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060161
  22. Godlewski J, 2010, CELL CYCLE, V9, P2742, DOI 10.4161/cc.9.14.12248
  23. Godlewski J, 2010, MOL CELL, V37, P620, DOI 10.1016/j.molcel.2010.02.018
  24. HENEINE W, 1992, J CLIN MICROBIOL, V30, P1605, DOI 10.1128/JCM.30.6.1605-1607.1992
  25. Huang SL, 2008, INT J CANCER, V123, P972, DOI 10.1002/ijc.23580
  26. Ivey KN, 2008, CELL STEM CELL, V2, P219, DOI 10.1016/j.stem.2008.01.016
  27. Jeong SJ, 2008, VIROLOGY, V370, P264, DOI 10.1016/j.virol.2007.09.003
  28. Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559
  29. KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121
  30. Kim VN, 2005, MOL CELLS, V19, P1
  31. Kim Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028293
  32. Kulkarni A, 2017, CELL CHEM BIOL, V24, P1377, DOI 10.1016/j.chembiol.2017.08.016
  33. Langenberger D, 2010, BIOCOMPUT-PAC SYM, P80
  34. Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200
  35. Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385
  36. Li JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085373
  37. Li XY, 2011, J EXP MED, V208, P663, DOI 10.1084/jem.20102384
  38. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  39. Ma G, 2013, ONCOGENE, V32, P4222, DOI 10.1038/onc.2012.450
  40. Ma GY, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0249-x
  41. Malone CD, 2009, CELL, V136, P656, DOI 10.1016/j.cell.2009.01.045
  42. Marquez RT, 2010, LAB INVEST, V90, P1727, DOI 10.1038/labinvest.2010.126
  43. Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551
  44. Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111
  45. Moles R, 2015, VIRUSES-BASEL, V7, P4047, DOI 10.3390/v7072805
  46. Moles R, 2015, NEOPLASIA, V17, P449, DOI 10.1016/j.neo.2015.04.005
  47. MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214
  48. Nakanishi K, 2016, WIRES RNA, V7, P637, DOI 10.1002/wrna.1356
  49. Nan Y, 2010, BRAIN RES, V1359, P14, DOI 10.1016/j.brainres.2010.08.074
  50. Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305
  51. Pessoa R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093374
  52. Pichler K, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-100
  53. POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
  54. Ruggero K, 2014, J VIROL, V88, P3612, DOI 10.1128/JVI.02823-13
  55. Ruggero K, 2010, MOL ASPECTS MED, V31, P367, DOI 10.1016/j.mam.2010.05.001
  56. Shadrach B, 2004, DIAGN MOL PATHOL, V13, P127, DOI 10.1097/01.pdm.0000126419.92931.a3
  57. Sharma VK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00832
  58. SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x
  59. de Lacerda TCS, 2016, CLIN EXP METASTAS, V33, P441, DOI 10.1007/s10585-016-9788-8
  60. Suarez Y, 2009, CIRC RES, V104, P442, DOI 10.1161/CIRCRESAHA.108.191270
  61. Takeda S, 2004, INT J CANCER, V109, P559, DOI 10.1002/ijc.20007
  62. Tomita M, 2012, INT J CANCER, V130, P2300, DOI 10.1002/ijc.25115
  63. Tomita N, 2012, BLOOD, V120, DOI 10.1182/blood.V120.21.1620.1620
  64. Vaz C, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-288
  65. Velu VK, 2012, J CLIN DIAGN RES, V6, P1791, DOI [10.7860/JCDR/2012/4241.2653, 10.7860/JCDR/2012/4901.2653]
  66. Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
  67. Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468
  68. Wang J, 2012, CELL RES, V22, P516, DOI 10.1038/cr.2011.132
  69. Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531
  70. Watanabe T, 2017, BLOOD, V129, P1071, DOI 10.1182/blood-2016-09-692574
  71. Whitman SP, 2010, BLOOD, V116, P3622, DOI 10.1182/blood-2010-05-283648
  72. Yamagishi M, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00334
  73. Yamagishi M, 2012, CANCER CELL, V21, P121, DOI 10.1016/j.ccr.2011.12.015
  74. Yamaguchi K, 2002, INT J HEMATOL, V76, P240, DOI 10.1007/BF03165123
  75. Yeh CH, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0518-2
  76. Yendamuri S, 2009, LEUKEMIA, V23, P1257, DOI 10.1038/leu.2008.382
  77. Yeung ML, 2008, CANCER RES, V68, P8976, DOI 10.1158/0008-5472.CAN-08-0769
  78. Yin KJ, 2015, CURR VASC PHARMACOL, V13, P352, DOI 10.2174/15701611113119990016
  79. Yin QY, 2010, J VIROL, V84, P6318, DOI 10.1128/JVI.00635-10
  80. YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534
  81. Zane L, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-114
  82. Zeng Y, 2015, INT J MOL MED, V36, P1639, DOI 10.3892/ijmm.2015.2367

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/03
Carregar mais